ImmuPharma plc (LON:IMM – Get Free Report) shares traded down 14.6% on Tuesday . The stock traded as low as GBX 3.20 ($0.04) and last traded at GBX 3.20 ($0.04). 13,200,714 shares changed hands during trading, a decline of 53% from the average session volume of 28,314,303 shares. The stock had previously closed at GBX 3.75 ($0.05).
ImmuPharma Stock Down 9.5 %
The stock has a market capitalization of £10.93 million, a P/E ratio of -262.50 and a beta of 1.53. The business’s 50 day simple moving average is GBX 1.54 and its two-hundred day simple moving average is GBX 1.68.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- Learn Technical Analysis Skills to Master the Stock Market
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- What Are Trending Stocks? Trending Stocks Explained
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
